This was the stock's third consecutive day of gains.

Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, weighed down by pricing pressure in the competitive North American market, their biggest ...

The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...